Guidelines for the Diagnosis and Management of Chronic Coronary Syndromes in Primary Health Care – the Issue of Acceptability for the Russian Federation
https://doi.org/10.18087/cardio.2020.4.n1000
Abstract
In 2019, the European Society for Cardiology (ESC) published guidelines with a new term, “chronic coronary syndromes” (CCS). These guidelines presented 6 clinical scenarios, which are most common in outpatient practice. The diagnostic approach described in these guidelines shifts from the standardization to the rationality of individualized solutions on using various diagnostic methods. The diagnostic approach suggested in the ESC guidelines requires extensive medical discussion and consensus because this will definitely entail a) further increase in indexes that reflect the morbidity of ischemic heart disease (IHD) due to unconfirmed diagnoses and b) administration of unreasoned therapy. This article presents statements of the guidelines, which cannot be automatically transmitted to the existing medical practice and should be discussed and adjusted by experts of the Russian Society of Cardiology.
About the Authors
O. M. Drapkina
National Medical Research Centre for Preventive Medicine, Ministry of Health of Russia
Russian Federation
Cheif
Russian Federation
Cheif
I. V. Samorodskaya
National Medical Research Centre for Preventive Medicine, Ministry of Health of Russia
Russian Federation
Chief Researcher
Russian Federation
Chief Researcher
V. N. Larina
Pirogov National Research Medical University, Ministry of Health of Russia,
Russian Federation
Head of Department of outpatient Medicine
Russian Federation
Head of Department of outpatient Medicine
References
1. Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. European Heart Journal. 2020;41(3):407–77. DOI: 10.1093/eurheartj/ehz425
2. American Hospital Association (AHA), American Health Information Management Association (AHIMA), CMS, NCHS. ICD-10-CM Official Guidelines for Coding and Reporting FY 2016. 2016. [Av. at: http://www.cdc.gov/nchs/data/icd/10cmguidelines_2016_final.pdf. ISBN: 978-1-329-60712-5]
3. Taqueti VR, Di Carli MF. Coronary Microvascular Disease Pathogenic Mechanisms and Therapeutic Options. Journal of the American College of Cardiology. 2018;72(21):2625–41. DOI: 10.1016/j.jacc.2018.09.042
4. Ezhumalai B, Ananthakrishnapillai A, Selvaraj RJ, Satheesh S, Jayaraman B. Cardiac syndrome X: Clinical characteristics revisited. Indian Heart Journal. 2015;67(4):328–31. DOI: 10.1016/j.ihj.2015.04.022
5. Kuruvilla S, Kramer CM. Coronary microvascular dysfunction in women: an overview of diagnostic strategies. Expert Review of Cardiovascular Therapy. 2013;11(11):1515–25. DOI: 10.1586/14779072.2013.833854
6. Löffler AI, Bourque JM. Coronary Microvascular Dysfunction, Microvascular Angina, and Management. Current Cardiology Reports. 2016;18(1):1. DOI: 10.1007/s11886-015-0682-9
7. Chowdhury M, Osborn EA. Physiological Assessment of Coronary Lesions in 2020. Current Treatment Options in Cardiovascular Medicine. 2020;22(1):2. DOI: 10.1007/s11936-020-0803-7
8. Morrow A, Sidik N, Berry C. ISCHEMIA: new questions from a landmark trial. Cardiovascular Research. 2020;116(2):e23–5. DOI: 10.1093/cvr/cvz343
9. Mathias IS, Riaz H. ISCHEMIA Trial: A Hope or a Hype for Patients with Stable Coronary Artery Disease? The American Journal of Medicine. 2019;S0002934319310800. [Epub ahead of print]. DOI: 10.1016/j.amjmed.2019.11.010
10. Fox KAA, Metra M, Morais J, Atar D. The myth of ‘stable’ coronary artery disease. Nature Reviews Cardiology. 2020;17(1):9–21. DOI: 10.1038/s41569-019-0233-y
11. Ministry of Health of Russian Federation. Clinical recommendations (CR155). Stable coronary heart disease. 2016. [Russian: Минздрав РФ. Клинические рекомендации (КР155). Стабильная ишемическая болезнь сердца] [Internet] 2016. Available at: http://cr.rosminzdrav.ru/#!/schema/133
12. Montalescot G, Sechtem W, Achenbach S, Andreotti F, Arden C, Budaj A et al. 2013 ESC guidelines on the management of stable coronary artery disease: The Task Force on the management of stable coronary artery disease of the European Society of Cardiology. European Heart Journal. 2013;34(38):2949–3003. DOI: 10.1093/eurheartj/eht296
13. Budoff MJ, Mayrhofer T, Ferencik M, Bittner D, Lee KL, Lu MT et al. Prognostic Value of Coronary Artery Calcium in the PROMISE Study (Prospective Multicenter Imaging Study for Evaluation of Chest Pain). Circulation. 2017;136(21):1993–2005. DOI: 10.1161/CIRCULATIONAHA.117.030578
14. Foldyna B, Udelson JE, Karády J, Banerji D, Lu MT, Mayrhofer T et al. Pretest probability for patients with suspected obstructive coronary artery disease: re-evaluating Diamond–Forrester for the contemporary era and clinical implications: insights from the PROMISE trial. European Heart Journal – Cardiovascular Imaging. 2019;20(5):574–81. DOI: 10.1093/ehjci/jey182
15. Reeh J, Therming CB, Heitmann M, Højberg S, Sørum C, Bech J et al. Prediction of obstructive coronary artery disease and prognosis in patients with suspected stable angina. European Heart Journal. 2019;40(18):1426–35. DOI: 10.1093/eurheartj/ehy806
16. Adamson PD, Newby DE, Hill CL, Coles A, Douglas PS, Fordyce CB. Comparison of International Guidelines for Assessment of Suspected Stable Angina. JACC: Cardiovascular Imaging. 2018;11(9):1301–10. DOI: 10.1016/j.jcmg.2018.06.021
17. Pavasini R, Camici PG, Crea F, Danchin N, Fox K, Manolis AJ et al. Anti-anginal drugs: Systematic review and clinical implications. International Journal of Cardiology. 2019;283:55–63. DOI: 10.1016/j.ijcard.2018.12.008
18. DuBroff R. Cholesterol paradox: a correlate does not a surrogate make. Evidence Based Medicine. 2017;22(1):15–9. DOI: 10.1136/ebmed-2016-110602
19. Ravnskov U, de Lorgeril M, Diamond DM, Hama R, Hamazaki T, Hammarskjöld B et al. LDL-C does not cause cardiovascular disease: a comprehensive review of the current literature. Expert Review of Clinical Pharmacology. 2018;11(10):959–70. DOI: 10.1080/17512433.2018.1519391
20. Cheung BMY, Lam KSL. Never too old for statin treatment? The Lancet. 2019;393(10170):379–80. DOI: 10.1016/S0140-6736(18)32263-3
21. Laleman N, Henrard S, van den Akker M, Goderis G, Buntinx F, Van Pottelbergh G et al. Time trends in statin use and incidence of recurrent cardiovascular events in secondary prevention between 1999 and 2013: a registry-based study. BMC Cardiovascular Disorders. 2018;18(1):209. DOI: 10.1186/s12872-018-0941-y
22. Wang SY, Tan ASL, Claggett B, Chandra A, Khatana SAM, Lutsey PL et al. Longitudinal Associations Between Income Changes and Incident Cardiovascular Disease: The Atherosclerosis Risk in Communities Study. JAMA Cardiology. 2019;4(12):1203–12. DOI: 10.1001/jamacardio.2019.3788
23. Eilat‐Tsanani S, Mor E, Schonmann Y. Statin Use Over 65 Years of Age and All‐Cause Mortality: A 10‐Year Follow‐Up of 19 518 People. Journal of the American Geriatrics Society. 2019;67(10):2038–44. DOI: 10.1111/jgs.16060
Review
For citations:
Drapkina O.M., Samorodskaya I.V., Larina V.N. Guidelines for the Diagnosis and Management of Chronic Coronary Syndromes in Primary Health Care – the Issue of Acceptability for the Russian Federation. Kardiologiia. 2020;60(4):130-136. (In Russ.) https://doi.org/10.18087/cardio.2020.4.n1000
Views:
8020
Email this article 
Post a Comment 
